SYSTEMATIC REVIEW: ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN FOLFOX-6 DAN FOLFOX-6 KOMBINASI BEVACIZUMAB® PADA PASIEN KANKER KOLOREKTAL METASTASE (mCRC) DARI BERBAGAI NEGARA

Sa’diyah, Khalimatus (2019) SYSTEMATIC REVIEW: ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN FOLFOX-6 DAN FOLFOX-6 KOMBINASI BEVACIZUMAB® PADA PASIEN KANKER KOLOREKTAL METASTASE (mCRC) DARI BERBAGAI NEGARA. Tesis thesis, Universitas Setia Budi Surakarta.

[img] Text
bab 2.pdf

Download (652kB)
[img] Text
bab 3.pdf

Download (273kB)
[img] Text
bab 4.pdf

Download (382kB)
[img] Text
bab 5.pdf

Download (91kB)
[img] Text
bab 6-lampiran.pdf

Download (158kB)
[img] Text
cover-bab 1.pdf

Download (604kB)
[img] Text
intisari-abstrak.pdf

Download (150kB)
[img] Text
lembar pernyataan publikasi.pdf

Download (283kB)

Abstract

Systematic review is a literature review method that identifies, assesses, interprets all findings of a research topic, to answer the research questions (reasearch question) that have been determined previously. This study aimed to determine the clinical goals of therapy and cost-effectiveness analysis of colorectal cancer metastase (mCRC) therapy used FOLFOX-6 and FOLFOX-6 combined with Bevacizumab® in various countries. This study used a Systematic review approach, which is a research method that identified, assessed and integrated all found regarding a research topic to address problems in a previously determined study. Systematic review in this study was carried out on the literature related to therapeutic analysis and the cost-effectiveness of mCRC treatment using FOLFOX-6 or FOLFOX-6 combined with Bevacizumab® in various countries. The search was carried out electronically using the PubMed and Embase databases. The results of this study indicate that mCRC therapy using FOLFOX-6 with the addition combination of bevacizumab® is better than FOLFOX-6 d in improves the quality of life of patients in a 5-20 years systematic review. ICER results on both FOLFOX-6 and FOLFOX-6 drugs with combination addition of Bevacizumab® to mCRC therapy in various countries showed that the addition of Bevacizumab® to FOLFOX-6 increased the cost to be more expensive but their use was more effective in healing and improving the quality of life of patients. Keyword: Systematic review, colorectal metastatic cancer, Bevacizumab®, FOLFOX, cost effectiveness analysis.

Item Type: Thesis (Tesis)
Uncontrolled Keywords: Systematic review, colorectal metastatic cancer, Bevacizumab®, FOLFOX, cost effectiveness analysis
Subjects: R Medicine > RA Public aspects of medicine
R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Divisions: Fakultas Farmasi > Prodi S2 Farmasi
Depositing User: Mrs NOVI HANDAYANI
Date Deposited: 13 Feb 2020 03:35
Last Modified: 13 Feb 2020 03:35
URI: http://repository.setiabudi.ac.id/id/eprint/4085

Actions (login required)

View Item View Item